RhumbLine Advisers’s Upstream Bio UPB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$224K Buy
42,445
+61
+0.1% +$399 ﹤0.01% 3207
2026
Q2
$293K Buy
42,384
+1,181
+3% +$9.9K ﹤0.01% 3081
2026
Q1
$371K Sell
41,203
-320
-0.8% -$5.76K ﹤0.01% 2793
2025
Q4
$1.13M Sell
41,523
-7,883
-16% -$196K ﹤0.01% 2164
2025
Q3
$929K Buy
49,406
+1,340
+3% +$20.8K ﹤0.01% 2291
2025
Q2
$528K Buy
48,066
+34,739
+261% +$321K ﹤0.01% 2655
2025
Q1
$81.6K Sell
13,327
-3,394
-20% -$32.4K ﹤0.01% 3454
2024
Q4
$275K Buy
+16,721
New +$373K ﹤0.01% 3041

Other funds holding UPB

RhumbLine Advisers's UPB Position: Q3 2026 in Review

RhumbLine Advisers increased its Upstream Bio (UPB) stake by 0.14% in Q3 2026, buying an estimated $399 and bringing the position to 42,445 shares worth $224K. The position accounts for ﹤0.01% of the portfolio, ranked #3207.

RhumbLine Advisers first reported a position in UPB in Q4 2024 and has held it in 8 quarters since. The position peaked at $1.13M in Q4 2025. 135 funds tracked by Wall St. Rank hold UPB as of Q3 2026.

  • RhumbLine Advisers held 42,445 shares of Upstream Bio worth $224K as of Q3 2026.
  • RhumbLine Advisers bought 61 Upstream Bio shares in Q3 2026, an estimated $399.
  • Upstream Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3207 holding.
  • RhumbLine Advisers first reported a position in Upstream Bio in Q4 2024 and has held it in 8 quarters since.
  • RhumbLine Advisers's Upstream Bio position peaked at $1.13M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Upstream Bio as of Q3 2026.

Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.